Lauren Massaro

Catch up on important pain management news from the month of July.

The new FDA-approved presentation will be the company’s third 505(b)(2) injectable added in 2024, expected to launch in the third quarter.

Lauren Adair, PharmD, director of network enablement at Outcomes, discussed developments in the expanding role of pharmacists amidst rising health care costs.

In case you missed it, this week we had news about drug expenditures, managing the peak asthma season, successes in HIV drugs, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

In the final part of his conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, reflects on 5-years worth of learnings at Skippack Pharmacy and offers candid perspectives on the future of community pharmacy.

In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.

In part 2 of his interview with Drug Topics featured on Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses how he redefined the role of a pharmacy at Skippack Pharmacy.

In part 1 of a recent conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, shared his journey from pharmacy school to pharmacy ownership.

The approval of eculizumab-aagh offers more treatment options for patients with rare diseases PNH and aHUS.

In case you missed it, this week we had news about cybersecurity breaches at Rite Aid, advancements in chronic hand eczema treatment, the Superman Pharmacist, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

The collaboration between Surescripts and DAW Systems leverages Surescripts’ established e-prescribing network, which last year processed 2.5 billion prescriptions from 1.29 million prescribers across the US.

The initiative by Boehringer and GoodRx has the potential to accelerate the therapeutic timeline for patients treated with the biosimilar.

In part 2 of the latest episode of Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses his journey as the Superman Pharmacist and expresses hope for the future of community pharmacy.

Mayank Amin, PharmD, RPh, MBA, sat down with Drug Topics on part 1 of an episode of Over the Counter to share his experiences transforming a shuttered independent pharmacy into a thriving community hub.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

In case you missed it, this week we had news about FTC-backed PBM investigations, FDA approvals in atopic dermatitis, misconceptions about dry eye, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Global coverage for diphtheria, tetanus, and pertussis has reached its lowest point in 15 years.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

The commercial product is expected to be available by the end of July.

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.